Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Angiogenesis and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3898
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Angiogenesis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Angiogenesis and Peptides.

    To find out more about Triple Analysis: Melanoma, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Access
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Baxter International
Bayer
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Biokine Therapeutics
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celtic Pharma
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
CSL
Cue Biotech
Curaxis
CureTech
Curis
Cyclacel
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
Dyax
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Flamel Technologies
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Hemispherx Biopharma
Hoffmann-La Roche
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Karyon-CTT
Kiadis
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Neurobiological Technologies
NewSouth Innovations
Nidus Laboratories
Non-industrial source
Novartis
Novelix
Novogen
Noxxon
NPS Pharmaceuticals
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Progen
Protagonist
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Serometrix
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
UCB
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Vectura
Vical
Wilex
VioQuest
WntResearch
Xerion
Xigen
York Pharma
Zelos Therapeutics
Zensun
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEB071
AEZS-108
afamelanotide
aflibercept
agatolimod
aldesleukin
ALT-801
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
APO-866
ARQ-197
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
BMS-663513
BMS-690514
BMS-936558
bortezomib
brivanib alaninate
Buparlisib
Cabozantinib
CB-10-01
CBP-501
cediranib
cilengitide
corticorelin acetate
cositecan
CT-011
dasatinib
decitabine
denenicokin
denileukin diftitox
deslorelin
DI-17E6
dinaciclib
dovitinib lactate
E-75
E-7820
E7449
EMD-273063
emepepimut-S
endostatin
ENMD-2076
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
everolimus
Exherin
foretinib
fosbretabulin tromethamine
FPI-01
fresolimumab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
GliaAtak
golvatinib
goserelin
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
GX-301
HBP-347
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
icrucumab
imatinib mesilate
imMucin
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
ISA-P53-01
ispinesib mesylate
JI-101
JX-594
kahalalide F
L19-IL2
Lambrolizumab
lanreotide
LEE-011
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LGX818
linifanib
LipoVIL12
LY-2275796
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
MKC-1106-MT
MORAb-004
motesanib diphosphate
muparfostat (IV)
NAFB001
netupitant
NGR-TNF
nilotinib
octreotide
octreotide, LAR
ON-01910
OncoVAX
OTS-102
ozarelix
P276-00
paclitaxel
PancAtak
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
perifosine
PF-4856884
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
RAF-265
ramucirumab
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
romurtide
sagopilone
sargramostim
SCIB-1
selumetinib
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
tesetaxel
thalidomide
thymalfasin
tipifarnib
tivozanib
TM-30339
trabedersen
TRC-105
tremelimumab
vandetanib
vapreotide, immediate-release
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647
YM-155
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Angiogenesis and Peptides.
    To find out more about Triple Analysis: Melanoma, Angiogenesis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Angiogenesis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Lung Cancer, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More


Brain Cancer Drug Pathway Analyzer
There are today at least 332 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways for the treatment of brain cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 235 drug targets that are included in this drug-pathway analyzing tool. No less than 229 of these have been recorded with mutations and 51 drug targets have mutations which have been causally implicated in cancer. Learn More